Osagrand (Sodium Ibandronate)

Osagrand is a bisphosphonate that acts on skeletal metabolism to reduce bone turnover.

• Osteoporosis: Improves bone mineral density and reduces fracture risk in post‑menopausal women and men at high risk.
• Bone metastases from solid tumours: Decreases incidence of skeletal‑related events such as pathological fractures.
• Hypercalcaemia of malignancy: Lowers serum calcium levels in patients with cancer‑related hypercalcaemia.

• Sodium Ibandronate binds selectively to hydroxy‑apatite crystals in bone, where it is internalised by osteoclasts during resorption. Once inside the cell, it inhibits farnesyl‑pyrophosphate synthase in the mevalonate pathway, disrupting prenylation of small GTP‑binding proteins and ultimately inducing osteoclast apoptosis, which reduces bone resorption.

Adverse reactions to Sodium Ibandronate are generally dose‑dependent and may vary with the route of administration.

Common Side Effects

• Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.
• Musculoskeletal pain: transient bone, joint or muscle aches.
• Flu‑like symptoms: mild fever, chills or fatigue.

Serious or Rare Side Effects

• Osteonecrosis of the jaw (ONJ): exposed necrotic bone in the oral cavity.
• Atypical femoral fractures: low‑energy fractures of the subtrochanteric region.
• Severe acute renal impairment: abrupt decline in kidney function.
• Hypocalcaemia: markedly low serum calcium levels requiring medical attention.

When prescribing Sodium Ibandronate, clinicians should consider patient‑specific factors and monitor for known risks.

• Renal function: assess baseline creatinine and adjust use in moderate to severe impairment.
• Calcium and vitamin D status: ensure adequate supplementation to reduce hypocalcaemia risk.
• Dental health: perform oral examination before initiating therapy and advise good oral hygiene.
• Concomitant medications: review for other agents that affect bone turnover or renal function.
• Pregnancy and lactation: avoid use unless clearly indicated, as safety data are limited.
• Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture.

Sodium Ibandronate may interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) combined with the oral formulation.
• Aminoglycoside‑   ...